However, the superior performance of CTSZ mRNA in PCa diagnosis observed in this study may have been influenced by the reduced sample size of this pilot study, associated with its retrospective nature, with the absence of a biopsy performance in the control group and the use of PSA as the leading guide for the pre-diagnostic selection of this group. This evidence concerns the gene CTSZ and posterior cortical atrophy.